ArticleEpilepsia open2020
Clinical outcomes and treatments effectiveness in status epilepticus resolved by antiepileptic drugs: A five-year observational study.
Article in Epilepsia open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open-label, dose-finding, phase 2 trial.Epilepsia · 2022Trial
- Neuroprotective effects of Vitamin D3 supplementation combination with valproate and perampanel in an experimental model using status epilepticus induction.Indian journal of pharmacology · 2026Article
- Underdosing and response to pharmacotherapy in patients with status epilepticus: a retrospective study from Saudi Arabia.Annals of medicine · 2025Article
- Pathophysiology of Status Epilepticus Revisited.International journal of molecular sciences · 2025Review
- Prognostic factors and impact of management strategies for status epilepticus: The STEPPER study in the Emilia-Romagna region, Italy.Epilepsia · 2025Observational
- Synthesis and Psychotropic Properties of Novel Condensed Triazines for Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Remote seizures and drug-resistant epilepsy after a first status epilepticus in adults.European journal of neurology · 2024Article
- Sustained effort network for treatment of status epilepticus/European academy of neurology registry on adult refractory status epilepticus (SENSE-II/AROUSE).BMC neurology · 2024Article
- Efficacy of Perampanel in Refractory and Super-Refractory Status Epilepticus with Suspected Inflammatory Etiology: A Case Series.Pharmaceuticals (Basel, Switzerland) · 2023Article
- How much refractory is 'refractory status epilepticus'? A retrospective study of treatment strategies and clinical outcomes.Journal of neurology · 2023Article
- Large-scale transient peri-ictal perfusion magnetic resonance imaging abnormalities detected by quantitative image analysis.Brain communications · 2023Article
- Development and Validation of a Nomogram Based on the Epidemiology-Based Mortality Score in Status Epilepticus (EMSE) Parameters to Predict 30-day Mortality in Status Epilepticus.Neurocritical care · 2022Article
- Status epilepticus with prominent motor symptoms clusters into distinct electroclinical phenotypes.European journal of neurology · 2021Article
- Review
- Optimizing status epilepticus care during the COVID-19 pandemic.Epilepsy & behavior : E&B · 2020Article
- Clinical outcomes and treatments effectiveness in status epilepticus resolved by antiepileptic drugs: A five-year observational study.Epilepsia open · 2020Article
- Perampanel use in pediatric autoimmune encephalitis-related seizures and epilepsy: a retrospective case series.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate clinical outcomes and treatment effectiveness of status epilepticus finally resolved by nonbenzodiazepine antiepileptic drugs (AEDs).
methodsAll consecutive SE episodes observed from September 1, 2013, to September 1, 2018, and resolved by AEDs were considered. Diagnosis and classification of SE followed the 2015 ILAE proposal. Nonconvulsive status (NCSE) diagnosis was confirmed according to the Salzburg EEG criteria. The modified Rankin Scale and deaths at 30 days from onset were used to evaluate outcomes.
resultsA total of 277 status episodes (mean age 71 years; 61% female) were treated and resolved by antiepileptic drugs after 382 treatment trials. 68% of the SE resolved after AED use as first/second treatment line, while subsequent trials with AEDs gave an additional 32% resolution. A return to baseline conditions was observed in 48% of the patients, while overall mortality was 19% without significant changes across the study years. Mortality was higher in NCSE than in convulsive SE (22.5% vs 12.9%; SIGNIFICANCE: A high short-term mortality, stable over time, was observed in SE despite resolution of seizures, especially in SE with nonconvulsive semiology. Comparative AED efficacy showed no significant differences except for higher resolution rate for valproate versus levetiracetam in NCSE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.